An Open-Label, Phase I/II, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Trial Profile

An Open-Label, Phase I/II, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Taselisib (Primary) ; Fulvestrant; Letrozole; Midazolam
  • Indications Advanced breast cancer; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 24 Nov 2017 Planned End Date changed from 30 Sep 2019 to 23 Nov 2022.
    • 24 Nov 2017 Planned primary completion date changed from 30 Sep 2019 to 23 Nov 2022.
    • 25 May 2017 Protocol has been amended to include changes in endpoint and changes in treatment arms from 5 to 6 .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top